Comparison of Two Assays to Determine Anti-Citrullinated Peptide Antibodies in Rheumatoid Arthritis in relation to Other Chronic Inflammatory Rheumatic Diseases: Assaying Anti-Modified Citrullinated Vimentin Antibodies Adds Value to Second-Generation Anti-Citrullinated Cyclic Peptides Testing

Table 1

General characteristics in patients with rheumatoid arthritis.

Characteristics	𝑁=142
Age in years, mean ± SD	49 ± 10.69
Women, 𝑛 (%)	135 (95)
Disease duration (years), mean ± DE	9 ± 8.07
DAS-28, mean ± SD	4.7 ± 1.5
DAS-28 > 3.2 𝑛 (%)	118 (83.1)
HAQ-DI, mean ± SD	0.91 ± 0.65
HAQ-DI > 1.25, 𝑛 (%)	38 (26.6)
Treatments
Methotrexate, 𝑛 (%)	48 (33.8)
Chloroquine, 𝑛 (%)	4 (2.8)
Leflunomide, 𝑛 (%)	17 (12)
Azathioprine, 𝑛 (%)	18 (14)
Etanercept, 𝑛 (%)	8 (5.6)
Glucocorticoids, 𝑛 (%)	124 (87.9)
Prednisone mg, mean ± SD	5.7 ± 1.6

SD: standard deviation, mg: milligrams.
DAS-28: disease activity score.
DAS-28: low activity ≤3.2; moderate activity >3.2 y ≤ 5.1; high activity >5.1.
HAQ-DI: Health Assessment Questionnaire-Disability Index: S.